The following is excerpted from the question-and-answer section of the transcript.
(Questions from industry analysts are provided in full, but answers are omitted - download the transcript to see the full question-and-answer session)
Question: Joseph Schwartz - Leerink Partners LLC - Analyst
: Great. Thanks so much and congrats on all the progress. Neurocrine seems to be doing quite well with the CRENESSITY launch. I was just wondering
how does that figure into your thinking about the pace of enrollment for your Phase 3 CAH studies now, if at all? And are there any particular kinds
of patients who are more likely to go on to CRENESSITY commercial versus enroll in a clinical study for atumelnant? Does that sound like for any
kinds of patients in your view?
Question: Joseph Schwartz - Leerink Partners LLC - Analyst
: Thanks for the call.
Question: Josh Schimmer - Cantor Fitzgerald LP - Analyst
: Thanks for taking the question. I guess given how much scrutiny there was on the cases of LFT elevation that we're seeing with atumelnant, can
you provide an update on the ongoing experience and whether that's been seen subsequently? And how do you plan on maintaining updates
going forward on that liver tox profile and whether it is turning into a meaningful signal or the opposite?
Question: Josh Schimmer - Cantor Fitzgerald LP - Analyst
: Thank you.
Question: Richard Law - Goldman Sachs Group Inc - Analyst
: Hey, guys. Good afternoon. How much do you think you can learn based on atumelnant's Cohort 4 with only 10 patients? And I assume there's
going to be data variability. Is there a chance to adjust the Phase 3 protocol based on what you learn in that Cohort 4 since you're starting the
Phase III study before you see the Phase 2 data? Thanks.
Question: Rohan Mathur - Oppenheimer & Co Inc - Analyst
: Hey. This is Rohan Mathur. Thanks for taking my question. At the moment, just given the timelines for the adult and pediatric trials, how does
Crinetics plan to manage the progression towards NDA submission and labeling discussions while incorporating the data from both of those studies
down the line? Thanks.
Question: Rohan Mathur - Oppenheimer & Co Inc - Analyst
: Got it. Thank you.
Question: Catherine Novack - Jonestrading Institutional Services LLC - Analyst
: Hey. Good afternoon, guys. Thanks for taking my question. I'm just curious on your thoughts on paltusotine in surgically naive patients based on
the AAC presentation. Is there a market here? Is there a significant number of patients who do forego surgical resection?
Question: Catherine Novack - Jonestrading Institutional Services LLC - Analyst
: Okay. Got it. Thanks.
REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us
consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies.
AUGUST 07, 2025 / 8:30PM, CRNX.OQ - Q2 2025 Crinetics Pharmaceuticals Inc Earnings Call
| 
